The global ivd raw materials market size was valued at USD 18.09 billion in 2025 and is projected to grow from USD 20.18 billion in 2026 to USD 48.38 billion by 2034, registering a CAGR of 11.55% during the forecast period from 2026 to 2034. North America dominated the ivd raw materials market with a market share of 30.18% in 2025.
The IVD raw materials market comprises essential biological, chemical, and synthetic components used in the production of in vitro diagnostic tests and analytical instruments. These materials support accurate disease detection and laboratory testing. They are widely used in molecular diagnostics, immunoassays, clinical chemistry, hematology, and point-of-care diagnostics across hospitals, laboratories, and research facilities.
The IVD raw materials market demand is increasing due to rising diagnostic testing, growing disease prevalence, and expanding healthcare services. Continuous product innovation, increasing investments in diagnostics, and stronger manufacturing capabilities are also contributing to IVD raw materials market growth.
Download a Free Sample To learn more about this report,
The IVD raw materials market is highly exposed to supply chain disruptions because it relies on globally sourced antibodies, antigens, enzymes, proteins, specialty chemicals, polymers, and laboratory-grade reagents that require strict quality control and regulatory compliance. Disruptions in the supply of these critical materials increase manufacturing lead times, delay diagnostic kit production, and raise procurement costs, affecting the timely availability of in vitro diagnostic products across healthcare facilities worldwide. On a global scale, manufacturers are strengthening regional sourcing strategies, diversifying supplier networks, investing in local production capabilities, and improving inventory management to enhance supply chain resilience. The market is expected to witness a capacity-constrained recovery, supported by expanding production capacity, improved supplier diversification, and the gradual stabilization of global raw material supply.
IVD manufacturers are increasingly transitioning from animal derived materials to recombinant proteins, monoclonal antibodies, and synthetic reagents to improve consistency, scalability, and regulatory compliance. This shift enhances batch to batch reproducibility while reducing risks associated with biological variability and contamination. As diagnostic testing expands globally, manufacturers are prioritizing standardized raw materials that support high performance assay development across multiple applications. For example, Thermo Fisher Scientific offers recombinant proteins and antibodies widely used in molecular and immunodiagnostic assay production.
The increasing use of molecular diagnostics and point-of-care testing is driving demand for high-purity enzymes, nucleotides, buffers, and specialty reagents with superior analytical performance. Manufacturers are focusing on raw materials that improve sensitivity, specificity, and stability to meet the growing need for rapid and accurate diagnostic results. This trend is supporting innovation in infectious disease, oncology, and genetic testing platforms. For example, New England Biolabs has expanded its portfolio of WarmStart RTx Reverse Transcriptase and Luna qPCR/RT-qPCR enzymes, which are specifically engineered for highly sensitive molecular diagnostic assays and point-of-care nucleic acid testing, enabling faster and more reliable PCR based detection.
Increasing Commercialization of Laboratory Developed Tests and Expansion of Contract Manufacturing for Diagnostic Kits Drives Market
The growing commercialization of laboratory developed tests is increasing demand for specialized IVD raw materials, including recombinant antigens, monoclonal antibodies, oligonucleotides, and custom enzymes. As hospitals, reference laboratories, and biotech companies develop disease-specific assays, they require high quality raw materials with consistent performance for validation and regulatory compliance. This trend is encouraging suppliers to expand custom reagent manufacturing and application-specific product portfolios, strengthening market demand. For example, the expansion of oncology and rare disease LDTs by laboratories has significantly increased procurement of custom antibodies and PCR-grade reagents from specialized raw material manufacturers.
The rapid growth of contract development and manufacturing organizations for diagnostic kits is accelerating demand for standardized IVD raw materials. Many diagnostic companies are outsourcing assay production, creating the need for reliable suppliers capable of delivering validated antibodies, enzymes, proteins, buffers, and specialty chemicals at commercial scale. This shift is strengthening long term procurement partnerships and increasing investments in high-volume raw material production. For example, contract manufacturers producing lateral flow assays and molecular diagnostic kits source GMP grade raw materials from suppliers such as Merck KGaA and Sartorius to ensure consistent manufacturing quality and regulatory compliance.
Complex Qualification Requirements and Limited Availability of High Affinity Biological Restrain Market Expansion
IVD manufacturers require every batch of antibodies, enzymes, proteins, and other critical raw materials to undergo extensive analytical validation before commercial use. Even minor variations in raw material characteristics can affect assay sensitivity, specificity, and reproducibility, making supplier replacement costly and time consuming. This discourages manufacturers from adopting alternative suppliers and extends product development timelines, limiting procurement flexibility and slowing market expansion. For example, molecular diagnostic manufacturers often revalidate entire PCR assay workflows when changing enzyme or primer suppliers, increasing both development costs and regulatory burden.
The production of biological raw materials, including monoclonal antibodies, recombinant proteins, and specialized enzymes, requires advanced manufacturing capabilities and rigorous quality control. Limited production capacity, lengthy development timelines, and complex purification processes create supply constraints for diagnostic manufacturers. These factors increase procurement costs, extend product development cycles, and delay the commercialization of new in vitro diagnostic assays, thereby restraining overall market growth.
Expansion of Companion Diagnostics and Rising Commercialization of CRISPR-Based Diagnostics Offer Growth Opportunities to Market Players
The rapid expansion of companion diagnostics is creating significant opportunities for suppliers of highly specialized IVD raw materials, including recombinant antigens, monoclonal antibodies, oligonucleotides, and molecular enzymes. As pharmaceutical companies increasingly co-develop targeted therapies with companion diagnostic assays, demand is rising for application specific raw materials that meet stringent analytical and regulatory requirements. This trend is encouraging long-term supply partnerships between raw material manufacturers and diagnostic developers. For example, the approval of companion diagnostics for targeted cancer therapies, such as those detecting EGFR, ALK, and BRCA biomarkers, has increased demand for highly validated molecular-grade enzymes and oligonucleotides used in PCR- and NGS-based assay manufacturing.
The commercialization of CRISPR based molecular diagnostics is creating a highly specialized opportunity for IVD raw material suppliers. Unlike conventional PCR assays, CRISPR diagnostics require proprietary guide RNAs, Cas enzymes, engineered nucleases, reporter molecules, and optimized reaction chemistries, opening new revenue streams for manufacturers of advanced biological reagents. For example, Mammoth Biosciences has developed CRISPR based DETECTR diagnostic platforms, driving demand for specialized Cas enzymes and synthetic guide RNA manufacturing that differs substantially from traditional IVD reagent requirements.
Ensuring Supply of Rare Biomarker Specific Reagents and Managing Cold Chain Stability Challenges Market Growth
The increasing development of highly specialized diagnostic assays has created challenges in securing a reliable supply of rare biomarker specific reagents. Many recombinant antigens, monoclonal antibodies, and reference materials are produced in limited volumes and require complex manufacturing processes. Supply shortages and extended production timelines can delay assay development, disrupt diagnostic kit manufacturing, and reduce the ability of manufacturers to rapidly respond to emerging clinical testing needs.
Many critical IVD raw materials, including enzymes, antibodies, and recombinant proteins, require tightly controlled cold-chain storage and transportation to preserve their biological activity. Temperature excursions during manufacturing, warehousing, or international shipping can reduce reagent stability and compromise diagnostic performance. Maintaining uninterrupted logistics increases operational costs, complicates global distribution, and creates significant challenges for suppliers serving geographically diverse diagnostic manufacturers.
Request Customizationto receive a tailored report.
Based on product, the antibody segment dominates the market with a revenue share of 47.23% in 2025, owing to their indispensable role in immunoassays, lateral flow diagnostics, and companion diagnostic development. Rising adoption of highly specific monoclonal antibodies, expanding biomarker-based testing, and increasing demand for multiplex immunodiagnostic platforms further strengthen this segment's leadership across clinical diagnostics.
The proteins segment is expected to grow at a CAGR of around 12.44% during the forecast period due to increasing use of recombinant proteins as assay calibrators, controls, and capture antigens in advanced diagnostics. Growing development of precision medicine assays and synthetic protein engineering continues accelerating demand across diagnostic manufacturing.
In 2025, immunochemistry accounted for a share of 34.54% in the IVD raw materials market, by technology. This is due to its extensive application in routine clinical diagnostics, increasing adoption of automated immunoassay analyzers, and growing use of high-sensitivity antigen antibody detection for endocrine, infectious disease, and cardiac biomarker testing.
The molecular diagnostics segment is expected to grow at a CAGR of 12.67% during the forecast period, driven by expanding utilization of PCR, digital PCR, and next generation sequencing technologies. Rising demand for genomic testing, antimicrobial resistance detection, and companion diagnostics is accelerating consumption of specialized molecular-grade raw materials.
By end user, pharmaceutical & biotechnology companies accounted for a share of 40.33% in 2025 due to increasing co-development of companion diagnostics with targeted therapies and expanding biomarker discovery programs. Continuous investments in assay development and clinical validation create sustained demand for premium-grade biological raw materials.
The diagnostic laboratories segment is expected to grow at a CAGR of 12.85% during the forecast period, driven by increasing test volumes requiring standardized reagent performance and laboratory automation. Growing adoption of high-throughput diagnostic workflows and accreditation requirements supports greater procurement of validated, high quality IVD raw materials.
Speak to an Analystto discuss market opportunities.
North America: Market Dominance Led by Established Diagnostic Manufacturing Infrastructure and Leadership in Molecular Diagnostics
The North America IVD raw materials market accounted for the largest regional share of 30.18% in 2025, driven by presence of leading life science companies, well established diagnostic manufacturing infrastructure, and continuous innovation in molecular and immunodiagnostic technologies. The region also benefits from robust biotechnology research, strong regulatory standards, and significant investments in precision medicine. According to the American Clinical Laboratory Association, clinical laboratories perform more than 14 billion laboratory tests annually in the US, supporting sustained demand for IVD raw materials.
The US IVD raw materials market was valued at USD 4.77 billion in 2025, driven by the country's leadership in molecular diagnostics, companion diagnostics, and laboratory developed test development. The presence of major diagnostic manufacturers, biotechnology companies, and contract manufacturing organizations continues to increase demand for premium antibodies, recombinant proteins, enzymes, and molecular reagents. Strong investments in precision medicine, oncology diagnostics, and genomic testing further support the adoption of advanced IVD raw materials across commercial and research applications.
The IVD raw materials market in Canada was valued at USD 687.90 million in 2025, supported by expanding biotechnology research, increasing domestic diagnostic manufacturing, and government initiatives promoting life sciences innovation. Growing collaborations between research institutions, healthcare organizations, and biotechnology companies are accelerating the development of advanced diagnostic assays requiring biological raw materials. The country's strong regulatory framework and increasing focus on precision healthcare continue to create favorable conditions for sustained market growth.
Asia Pacific: Fastest Growth Driven by Rising Biotechnology Investments and Growing Production of Molecular & Immunodiagnostic Kits
The Asia Pacific IVD raw materials market is expected to grow at a CAGR of 13.55% during the forecast period, showcasing the fastest regional growth. Growth is supported by expanding diagnostic manufacturing capacity, rising biotechnology investments, and increasing production of molecular and immunodiagnostic kits across the region. Governments are strengthening local life sciences capabilities to reduce import dependence and enhance healthcare resilience. According to Japan's Ministry of Health, Labour and Welfare, more than 70,000 clinical laboratories operate across hospitals and healthcare facilities, supporting sustained market growth.
The China IVD raw materials market was valued at USD 978.69 million in 2025, supported by rapid expansion of domestic diagnostic manufacturers and increasing government initiatives to strengthen the country's biotechnology and life sciences sectors. Growing production of molecular diagnostics, immunoassays, and point-of-care testing products is increasing demand for recombinant proteins, antibodies, enzymes, and specialty reagents. Rising investments in localized raw material manufacturing are further reducing reliance on imported diagnostic components.
The India IVD raw materials market was valued at USD 517.34 million in 2025, fueled by expanding domestic diagnostic kit manufacturing and increasing investments under biotechnology and healthcare initiatives. Growing demand for affordable molecular diagnostics, infectious disease testing, and preventive healthcare is encouraging manufacturers to strengthen local production of biological reagents and specialty chemicals. The rapid expansion of contract manufacturing organizations is further supporting market growth.
The Japan IVD raw materials market was valued at USD 596.90 million in 2025, supported by advanced biotechnology industry and strong focus on high quality diagnostic innovation. Manufacturers emphasize premium biological raw materials with superior purity and analytical performance to support precision diagnostics and laboratory automation. Continuous investment in molecular diagnostics, aging-related disease testing, and research collaborations continue to strengthen demand for advanced IVD raw materials across the country.
Unlock Regional Insightsto access country-level data, & regional trends.
The IVD raw materials market competitive landscape is moderately consolidated, with competition centered among global life science companies, biotechnology firms, and specialized reagent manufacturers supplying high-quality biological and chemical materials for diagnostic applications. Leading players compete through proprietary technologies, product purity, manufacturing scalability, regulatory compliance, and long-term partnerships with diagnostic kit manufacturers. The IVD raw materials market ecosystem is shaped by increasing demand for molecular diagnostics, stringent quality standards, continuous innovation in biological reagents, expanding contract manufacturing, and the need for reliable supply chains that ensure consistent performance across diverse in vitro diagnostic platforms.
February 2026: Sysmex Corporation and Fujirebio Holdings began a sales collaboration agreement for dementia testing, under which Sysmex will commercialize Fujirebio's Lumipulse immunoassay systems and dementia-related reagents across selected global markets, expanding access to advanced immunodiagnostic solutions.
August 2025: Thermo Fisher Scientific opened a new 375,000 square-foot Manufacturing Center of Excellence in Mebane, North Carolina, expanding production capacity for laboratory consumables and strengthening the life sciences and diagnostic manufacturing supply chain.
Customize This Report to Match Your Strategic Objectives
Author's Details
Research Associate
Mitiksha Koul is a Research Associate with 2 years of experience in market research. She focuses on analyzing industry trends, competitive landscapes, and growth opportunities to support strategic decision-making. Mitiksha’s strong analytical skills and research expertise enable her to deliver actionable insights that help businesses adapt to evolving market dynamics and achieve sustainable growth.
We are featured on:
sales@straitsresearch.com